NOVEL NANOPARTICLES OF ANTIRETROVIRAL DRUGS, THEIR PREPARATION AND THEIR USE FOR THE TREATMENT OF VIRAL INFECTIONS
Nanoparticles comprising an antiretroviral drug such as AZT-TP or enfuvirtide encapsulated by a complex of chitosan and optionally a metal cation such as Fe3+, for use in treating or preventing HIV infection via subcutaneous or intramuscular administration. The nanoparticles have a size less than 300 nm and a high drug loading capacity between 20-60% by weight. They are prepared by mixing an aqueous solution of chitosan and metal cation with an aqueous solution of the drug. The chitosan-based nanoparticles provide an effective method to deliver antiretroviral drugs to key HIV reservoir sites with high drug loading and low toxicity.
1 . A nanoparticle comprising an antiretroviral drug encapsulated by an encapsulation complex, said complex comprising chitosan and a metal cation.
2 . The nanoparticle according to claim 1 where said antiretroviral drug is AZT-TP.
3 . The nanoparticle according to claim 1 where said metal cation is Fe 3+ .
4 . The nanoparticle according to claim 1 having a mean diameter in number or in intensity of less than 300 nm.
5 . The nanoparticle according to claim 1 comprising from 20 to 60% of antiretroviral drug in weight.
6 . The nanoparticle according to claim 1 where the maximum ratio of the amount of the antiretroviral drug in the nanoparticle relative to the amount of the chitosan in the nanoparticle is comprised between 0.03 and 0.3.
7 . The nanoparticle of claim 1 , comprising from 1 to 20% of Fe in weight with respect to the weight of the chitosan/Fe complex.
8 . A pharmaceutical composition comprising a nanoparticle according to claim 1 .
9 . The process of preparation of a nanoparticle of claim 1 comprising mixing a S1 aqueous solution of chitosan with a S2 aqueous solution of said antiretroviral drug.
10 . The process of claim 9 , wherein the mixing step further comprises mixing a metal cation, with the S1 queous solution and the S2 aqueous solution.
11 . A nanoparticle comprising enfuvirtide encapsulated by an encapsulation complex comprising chitosan.
12 . The nanoparticle of claim 11 , wherein the encapsulation complex comprises chitosan and one or more metal cation.
13 . The nanoparticle according to claim 11 comprising from 20 to 60% of enfuvirtide drug in weight.
14 . A nanoparticle comprising AZT-TP encapsulated by an encapsulation complex, said complex comprising chitosan and Fe3+, wherein the nanoparticle has a mean diameter in number or in intensity of less than 300 nm and comprises from 20 to 60% of antiretroviral drug in weight and from 1 to 20% of Fe in weight with respect to the weight of the chitosan/Fe complex.